Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); WORLD 2012: ERT Combo Proof of Concept
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Price: $14.49 --0%
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amicus Therapeutics (NASDAQ: FOLD) price target of $10.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on potential positive migalastat pivotal Fabry monoTx data Q3/12, Amigal market potential as mono/combo therapy for Fabry disease, AT2220’s potential in Pompe. We think Q3/12 pivotal Fabry monoTx ‘011 trial data for migalastat (fka Amigal) will be a strong, positive, transformational catalyst. We think ‘011 has a high chance of success on Phase 2 precedent, patient enrichment, and better quantification technology. We also expect good top-line Phase 2 proof-of-concept AT2220/ERT Pompe combo data in H1/12, similar to the positive Fabry data at WORLD."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $6.70 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on potential positive migalastat pivotal Fabry monoTx data Q3/12, Amigal market potential as mono/combo therapy for Fabry disease, AT2220’s potential in Pompe. We think Q3/12 pivotal Fabry monoTx ‘011 trial data for migalastat (fka Amigal) will be a strong, positive, transformational catalyst. We think ‘011 has a high chance of success on Phase 2 precedent, patient enrichment, and better quantification technology. We also expect good top-line Phase 2 proof-of-concept AT2220/ERT Pompe combo data in H1/12, similar to the positive Fabry data at WORLD."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $6.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
- Morgan Stanley Downgrades Nichirei Corp (2871:JP) to Equalweight
- Lululemon (LULU) PT Lowered to $120 at UBS on Expectations for Lowered FY26 Guidance
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
